UK’s NICE Supports Amvuttra for Hereditary ATTR Amyloidosis
According to a story on pharmaphorum.com, the UK's National Institute for Health and Care Excellence (NICE) has given a positive opinion for the drug vutrisiran (marketed as Amvuttra) as a…